Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
You may also be interested in...
AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.
Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.